NCT05961397 - Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 10, 2021

Primary Completion Date

April 15, 2022

Study Completion Date

April 15, 2022

Conditions

Hypertension

Interventions

DRUG

baxdrostat

single oral dose of baxdrostat 10 mg

Trial Locations (5)

Orlando Clinical Research Center, Orlando

Advanced Pharma CR, Miami

Alliance for Multispecialty Research, Knoxville

American Research Corporation at the Texas Liver Institute, San Antonio

Inland Empire Clinical Trials, Rialto